Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines (Nasdaq: PRAX) announced on October 1, 2025 that its Compensation Committee granted restricted stock unit awards covering an aggregate of 4,200 shares to three new non‑executive employees under the 2024 Inducement Plan.
The awards were granted as inducements material to the employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest in four equal annual installments, subject to the recipients' continued employment on each vesting date. The 2024 Inducement Plan is reserved exclusively for equity awards to newly hired individuals or those returning after a bona fide break in service.
Praxis Precision Medicines (Nasdaq: PRAX) ha annunciato il 1 ottobre 2025 che il suo Compensation Committee ha concesso premi in azioni vincolate per un totale di 4.200 azioni a tre nuovi dipendenti non esecutivi nell’ambito del Piano Inducement 2024.
I premi sono stati concessi come elementi di induzione per l’assunzione dei dipendenti in conformità al Nasdaq Listing Rule 5635(c)(4). Le unità azionarie vincolate matureranno in quattro rate annuali uguali, soggette al mantenimento del rapporto di lavoro da parte dei beneficiari in ciascuna data di maturazione. Il Piano Inducement 2024 è riservato esclusivamente a premi azionari per persone neoassunte o per coloro che ritornano dopo un periodo di servizio effettivo interrotto.
Praxis Precision Medicines (Nasdaq: PRAX) anunció el 1 de octubre de 2025 que su Compensation Committee otorgó premios de unidades de acciones restringidas por un total de 4.200 acciones a tres nuevos empleados no ejecutivos bajo el Plan de Inducción 2024.
Los premios se otorgaron como incentivos para la entrada de los empleados en el empleo de acuerdo con la Regla 5635(c)(4) de la lista de Nasdaq. Las unidades de acciones restringidas vencerán en cuatro cuotas anuales iguales, sujeto a que los destinatarios permanezcan empleados en cada fecha de vencimiento. El Plan de Inducción 2024 está reservado exclusivamente para premios de acciones para personas recién contratadas o que regresan tras una interrupción de servicio de buena fe.
Praxis Precision Medicines (나스닥: PRAX)는 2025년 10월 1일에 보상위원회가 4,200주의 주식보상계약(RSU)을 신규 비임원 직원 3명에게 2024년 유도 계획에 따라 부여했다고 발표했습니다.
이 보상은 Nasdaq Listing Rule 5635(c)(4)에 따라 직원 채용의 유도책으로 부여되었습니다. 주식보상계약은 매년 4회로 균등하게 비례 vest되며, 각 vesting 날짜에 수혜자의 계속 고용이 전제됩니다. 2024년 유도 계획은 신규 채용자나 정당한 휴직 후 복귀하는 사람들에게만 주식 보상을 위한 것으로 예약되어 있습니다.
Praxis Precision Medicines (Nasdaq : PRAX) a annoncé le 1er octobre 2025 que son Comité de rémunération avait accordé des attributions d’unités d’actions restreintes couvrant un total de 4 200 actions à trois nouveaux employés non cadres dans le cadre du Plan 2024 d’induction.
Les attributions ont été accordées comme incitations à l’entrée en emploi conformément à la Règle 5635(c)(4) de la cotation Nasdaq. Les unités d’actions restreintes vestent en quatre versements annuels égaux, sous réserve du maintien de l’emploi par les bénéficiaires à chaque date d’acquisition. Le Plan d’induction 2024 est réservé exclusivement aux attributions d’actions pour les personnes nouvellement embauchées ou celles revenant après une interruption réelle de service.
Praxis Precision Medicines (Nasdaq: PRAX) gab am 1. Oktober 2025 bekannt, dass sein Vergütungsausschuss RSI-Zuteilungen (Restricted Stock Unit) über insgesamt 4.200 Aktien an drei neue nichtleitende Mitarbeiter im Rahmen des 2024 Inducement Plan gewährt hat.
Die Zuteilungen wurden als Anreize für den Eintritt der Mitarbeiter in das Unternehmen gemäß der Nasdaq Listing Rule 5635(c)(4) gewährt. Die Restricted-Stock-Units vesten in vier gleichen jährlichen Raten, vorbehaltlich der fortgesetzten Anstellung der Empfänger zu jedem Vesting-Datum. Der 2024 Inducement Plan ist ausschließlich für Aktienzuwendungen für neu eingestellte Personen oder jene, die nach einer bona fide Unterbrechung der Dienstzeit zurückkehren, vorgesehen.
Praxis Precision Medicines (ناسداك: PRAX) أعلن عن 1 أكتوبر 2025 أن لجنة التعويضات لديها منحت جوائز وحدات أسهم مقيدة تغطي إجمالاً 4,200 سهم لثلاثة موظفين جدد غير تنفيذيين بموجب خطة التحفيز 2024.
تم منح الجوائز كحوافز للالتحاق بالعمل وفقاً لقاعدة إدراج ناسداك 5635(c)(4). ستتقيد وحدات الأسهم المقيدة بالانطلاق في أربعة أقساط سنوية متساوية، مع شرط استمرار التوظيف لدى المستفيدين في كل تاريخ تقييد. تُخصص خطة التحفيز 2024 حصرياً للمكافآت بالأسهم للأشخاص الجدد الذين تم توظيفهم أو لأولئك العائدين بعد انقطاع بنية الخدمة الفعلية.
Praxis Precision Medicines (纳斯达克：PRAX) 宣布于 2025年10月1日，其薪酬委员会批准向三名新聘非执行员工在2024 引进计划 下授予总计 4,200 股 的受限股票单位。
这些授予作为进入雇佣的诱因，符合 纳斯达克上市规则5635(c)(4)。受限股票单位将分四个等额年度归属，前提是受益人在每个归属日仍然受雇。2024 引进计划 专门用于新聘人员或在实际服务中断后回归的人员的股票奖励。
- None.
- None.
BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on October 1, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 4,200 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
Contacts: Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
What did Praxis (PRAX) announce on October 2, 2025 about inducement grants?
How do the Praxis PRAX restricted stock units vest and when do they vest?
Why were the Praxis PRAX awards granted under Nasdaq Listing Rule 5635(c)(4)?
Do the Praxis PRAX inducement grants indicate a change to the company’s equity plan?
Will the Praxis PRAX RSU grants cause immediate dilution to shareholders?
Who received the Praxis PRAX inducement RSUs and were they executives?
